MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) Short Interest Down 13.9% in February

MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) saw a large decrease in short interest in February. As of February 27th, there was short interest totaling 489,206 shares, a decrease of 13.9% from the February 12th total of 568,283 shares. Approximately 1.3% of the company’s stock are short sold. Based on an average daily volume of 98,615 shares, the days-to-cover ratio is currently 5.0 days. Based on an average daily volume of 98,615 shares, the days-to-cover ratio is currently 5.0 days. Approximately 1.3% of the company’s stock are short sold.

Analysts Set New Price Targets

MIRA has been the topic of a number of research reports. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of MIRA Pharmaceuticals in a research note on Monday, December 29th. Rodman & Renshaw began coverage on MIRA Pharmaceuticals in a research note on Tuesday, January 13th. They issued a “buy” rating for the company. Finally, Wall Street Zen lowered MIRA Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, November 22nd. One equities research analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, MIRA Pharmaceuticals currently has an average rating of “Hold”.

MIRA Pharmaceuticals Trading Up 0.2%

MIRA Pharmaceuticals stock traded up $0.00 during trading on Tuesday, hitting $1.21. 34,127 shares of the company were exchanged, compared to its average volume of 140,697. The company has a market capitalization of $50.80 million, a P/E ratio of -0.79 and a beta of 1.78. The business’s 50 day moving average is $1.29 and its 200 day moving average is $1.39. MIRA Pharmaceuticals has a 52 week low of $0.73 and a 52 week high of $2.45.

Institutional Trading of MIRA Pharmaceuticals

Several institutional investors and hedge funds have recently made changes to their positions in the company. Geode Capital Management LLC lifted its position in shares of MIRA Pharmaceuticals by 100.0% during the fourth quarter. Geode Capital Management LLC now owns 272,878 shares of the company’s stock valued at $412,000 after purchasing an additional 136,438 shares in the last quarter. First American Bank grew its position in MIRA Pharmaceuticals by 150.0% in the 3rd quarter. First American Bank now owns 50,000 shares of the company’s stock worth $68,000 after purchasing an additional 30,000 shares in the last quarter. Two Sigma Investments LP increased its stake in MIRA Pharmaceuticals by 129.8% in the 3rd quarter. Two Sigma Investments LP now owns 45,703 shares of the company’s stock valued at $62,000 after buying an additional 25,816 shares during the last quarter. Creative Planning purchased a new stake in MIRA Pharmaceuticals in the 2nd quarter valued at about $27,000. Finally, XTX Topco Ltd bought a new position in shares of MIRA Pharmaceuticals during the 2nd quarter worth approximately $26,000. Hedge funds and other institutional investors own 35.16% of the company’s stock.

About MIRA Pharmaceuticals

MIRA Pharmaceuticals, Inc operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a patent pending oral ketamine analog under investigation to deliver ultra-rapid antidepressant effects for individuals battling treatment-resistant depression, major depressive disorder with suicidal ideation, and post-traumatic stress disorder.